These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8010899)

  • 1. Results of external beam radiotherapy in 448 patients with clinically localized adenocarcinoma of the prostate.
    Mameghan H; Fisher R; Mameghan J; Brook S
    Aust N Z J Surg; 1994 Jun; 64(6):389-94. PubMed ID: 8010899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenocarcinoma of the prostate treated with external-beam radiation therapy: 5-year minimum follow-up.
    Amdur RJ; Parsons JT; Fitzgerald LT; Million RR
    Radiother Oncol; 1990 Jul; 18(3):235-46. PubMed ID: 2120741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymph node-positive prostate cancer: evaluation of the results of the combination of androgen deprivation therapy and radiation therapy.
    Buskirk SJ; Pisansky TM; Atkinson EJ; Schild SE; O'Brien PC; Wolfe JT; Zincke H
    Mayo Clin Proc; 2001 Jul; 76(7):702-6. PubMed ID: 11444402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of treatment for prostate carcinoma by staging pelvic lymph node dissection and definitive irradiation using low-dose rate temporary iridium-192 interstitial implant and external beam radiotherapy.
    Puthawala AA; Syed AM; Austin PA; Cherlow JM; Perley JM; Shanberg AM; Sawyer DE; Ingram JE; Baghdassarian R; Wachs BH; Perley JE; Londrc A; Espinoza-Ferrel T
    Cancer; 2001 Oct; 92(8):2084-94. PubMed ID: 11596024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate.
    Perez CA; Michalski J; Brown KC; Lockett MA
    Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):573-84. PubMed ID: 8948341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
    Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
    Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complications following external beam radiation therapy for prostate cancer: an analysis of patients treated with and without staging pelvic lymphadenectomy.
    Greskovich FJ; Zagars GK; Sherman NE; Johnson DE
    J Urol; 1991 Sep; 146(3):798-802. PubMed ID: 1908530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems.
    Le QT; Fu KK; Kaplan M; Terris DJ; Fee WE; Goffinet DR
    Cancer; 1999 Nov; 86(9):1700-11. PubMed ID: 10547542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy.
    Zagars GK; von Eschenbach AC; Ayala AG
    Cancer; 1993 Sep; 72(5):1709-25. PubMed ID: 7688659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer.
    Galalae RM; Kovács G; Schultze J; Loch T; Rzehak P; Wilhelm R; Bertermann H; Buschbeck B; Kohr P; Kimmig B
    Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):81-90. PubMed ID: 11777625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moderate hypofractionated external beam radiotherapy alone for intermediate risk prostate cancer: long term outcomes.
    Faria SL; Neto OB; Cury F; Shenouda G; Russel R; Souhami L
    Can J Urol; 2016 Apr; 23(2):8209-14. PubMed ID: 27085825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose-rate brachytherapy as monotherapy for localized prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity.
    Yoshioka Y; Nose T; Yoshida K; Oh RJ; Yamada Y; Tanaka E; Yamazaki H; Inoue T; Inoue T
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):213-20. PubMed ID: 12694841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer.
    Kupelian PA; Mohan DS; Lyons J; Klein EA; Reddy CA
    Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):567-74. PubMed ID: 10701735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy.
    Zagars GK; Ayala AG; von Eschenbach AC; Pollack A
    Int J Radiat Oncol Biol Phys; 1995 Jan; 31(2):237-45. PubMed ID: 7836075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.
    Zagars GK; Pollack A; Smith LG
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):809-19. PubMed ID: 10386637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transperineal percutaneous iridium-192 interstitial template implant of the prostate: results and complications in 321 patients.
    Khan K; Thompson W; Bush S; Stidley C
    Int J Radiat Oncol Biol Phys; 1992; 22(5):935-9. PubMed ID: 1555985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External beam radiotherapy dose response of prostate cancer.
    Pollack A; Zagars GK
    Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1011-8. PubMed ID: 9392538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in prostate cancer survival over time: a 20-year analysis.
    Kim MM; Hoffman KE; Levy LB; Frank SJ; Pugh TJ; Choi S; Nguyen QN; McGuire SE; Lee AK; Kuban DA
    Cancer J; 2012; 18(1):1-8. PubMed ID: 22290249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morbidity and mortality of local failure after definitive therapy for prostate cancer.
    Schellhammer PF; Whitmore RB; Kuban DA; el-Mahdi AM; Ladaga LA
    J Urol; 1989 Mar; 141(3):567-71. PubMed ID: 2918594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.